Semaglutide (Ozempic) is a GLP-1 medication designed to support weight loss by reducing appetite, controlling cravings, and promoting sustainable fat loss
In March, the Food and Drug Administration approved Vykat XR, an extended-release version of the existing drug diazoxide choline, which eases the relentless hunger and may offer insights into the biology of extreme appetite and binge eating
GHRP-6s NPY/AgRP activation introduces a variable that can independently modulate GH pulse frequency in certain model contexts a subtle but real confound in studies where pulse frequency, not just amplitude, is a primary endpoint
TDM received research funding from the German Research Foundation (DFG) within TRR-152 (P23) and TRR-296 and the German Center for Diabetes Research (DZD), and the European Union (ERC CoG) TRUSTED 101044445
GHRP-6 also strongly stimulates appetite via hypothalamic pathways